You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Measuring Progress in Neglected Disease Drug Development
|
|---|---|
| Published in |
Clinical Therapeutics, June 2014
|
| DOI | 10.1016/j.clinthera.2014.05.004 |
| Pubmed ID | |
| Authors |
Joshua P. Cohen, Greg Sturgeon, Alisa Cohen |
| Abstract |
Since the late 1990s, funding for development of neglected disease drugs has increased with an influx of resources from product development partnerships (PDPs). Previous research showed modest gains in drug approvals and products in Phase III of clinical development in the period 2000-2008. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 2% |
| Unknown | 114 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 32 | 28% |
| Student > Ph. D. Student | 16 | 14% |
| Student > Bachelor | 14 | 12% |
| Researcher | 7 | 6% |
| Student > Postgraduate | 7 | 6% |
| Other | 21 | 18% |
| Unknown | 19 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 17% |
| Chemistry | 17 | 15% |
| Agricultural and Biological Sciences | 13 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Other | 28 | 24% |
| Unknown | 25 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2014.
All research outputs
#2,039,124
of 25,373,627 outputs
Outputs from Clinical Therapeutics
#187
of 3,850 outputs
Outputs of similar age
#19,825
of 242,006 outputs
Outputs of similar age from Clinical Therapeutics
#2
of 58 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,850 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,006 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.